DRUG UTILIZATION DATA IN RISK BENEFIT ANALYSES OF DRUGS - SESSION-III - DISCUSSION

被引：0
|
作者：
CROUT, R
WIHOLM, BE
SHAPIRO, S
INMAN, WHW
VESSEY, M
HALL, RC
JONES, JK
CROOKS, J
WADE, OL
SKEGG, D
DUKES
FRIEBEL
HJORT, P
SJOQVIST, F
HEKSTER
BIRKETT
机构：
来源：
ACTA MEDICA SCANDINAVICA | 1984年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：149 / 152
页数：4
相关论文
共 50 条
  • [21] EVIDENCE FOR INFLUENCE OF SULFUR-OXIDES AND PARTICULATES ON MORBIDITY - GENERAL DISCUSSION - SESSION-III
    EISENBUD, M
    KNELSON, J
    FERRIS, BG
    HACKNEY, JD
    SHY, CM
    COLUCCI, A
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1978, 54 (11) : 1186 - 1198
  • [22] PANEL-I DISCUSSION - SESSION-III - PROTECTIVE VALUE OF POTASSIUM-IODIDE
    BECKER, DV
    ROBBINS, J
    SHLEIEN, B
    YALOW, RS
    MATUSZEK, J
    SAENGER, E
    MACDOUGALL, AD
    WEINBERG, AM
    SOLON, L
    HULL, AP
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1983, 59 (10) : 1039 - 1047
  • [23] SESSION-III - ROUND-TABLE - WHERE DO WE GO FROM HERE - GENERAL DISCUSSION
    TURTURRO, A
    WEISBURGER
    KRITCHEVSKY, D
    MACDONALD, P
    GRAHAM, S
    GREENWALD, P
    NEWMARK, H
    POIRIER, LA
    WILLETT, C
    ZIEGLER, R
    ENIG, M
    GROSSMAN, G
    CARROLL, KK
    WEINHOUSE
    KOLONEL, LN
    DODSON, D
    HARPER, AE
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1987, 45 (01): : 367 - 372
  • [24] METHODS FOR ASSESSING DRUG UTILIZATION - SESSION-I - DISCUSSION
    WADE, OL
    VESSEY, M
    STANULOVIC, M
    NORELL, S
    JONES, JK
    CROOKS, J
    SHAPIRO, S
    STRANDBERG
    CROUT, R
    SKEGG, D
    LILJETRAND, A
    ACTA MEDICA SCANDINAVICA, 1984, : 41 - 42
  • [25] ESOPHAGEAL MANOMETRY - METHODS AND VALUE IN SCIENCE AND CLINICAL-PRACTICE .3. DRUG EFFECTS ON ESOPHAGEAL SMOOTH-MUSCLE - DISCUSSION - SESSION-III
    BALDI, F
    JANISCH, HD
    KUHLMANN, J
    STACHER, G
    ERCKENBRECHT, JF
    SMOUT, AJPM
    FEUSSNER, H
    WEIHRAUCH, TR
    BAUNACK, AR
    MITTAL, RK
    JANSSENS, J
    EMDE, C
    KONRADDALHOFF, I
    AKKERMANS, LMA
    DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (09) : S84 - S87
  • [26] BENEFIT RISK RATIO OF NEW DRUGS - FOR WHOM - DISCUSSION PAPER
    PALMINTERI, R
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (03) : 155 - 157
  • [27] INTERPRETATION OF RESULTS FROM DRUG UTILIZATION STUDIES - SESSION-II - DISCUSSION
    SHAPIRO, S
    SKEGG, D
    CROOKS, J
    JONES, JK
    WADE, OL
    HJORT, P
    GROSS, F
    ACTA MEDICA SCANDINAVICA, 1984, : 101 - 101
  • [28] PANEL DISCUSSION - SESSION-III - REQUIREMENTS FOR AN EFFECTIVE NUTRITION TEACHING PROGRAM IN MEDICAL-SCHOOLS - ESSENTIAL PERSONNEL AND MEDICAL-CENTER RESOURCES
    PISUNYER, FX
    KNITTLE, J
    KUPERMAN, A
    LEVY, M
    RIVLIN, R
    YOUNG, E
    BATEMAN, B
    SHILS, M
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1984, 60 (06) : 675 - 686
  • [29] DRUG-MONITORING - REQUIREMENTS FOR RISK BENEFIT ESTIMATION FOR DRUGS
    SCHONHOFER, PS
    FRESENIUS ZEITSCHRIFT FUR ANALYTISCHE CHEMIE, 1982, 311 (04): : 314 - 314
  • [30] Benefit and risk assessment in drug development and utilization: A role for clinical pharmacology
    Honig, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (02) : 109 - 112
12345